February 1, 2024 Press release - Non-regulatory The first patient has been dosed in Circio’s TG01 triple combination study
November 16, 2023 Press release - Non-regulatory Circio inngår nytt samarbeid i USA for å teste kreftvaksinen TG01 i RAS-mutert kreft
February 8, 2023 Press release - Regulatory Targovax ASA: Invitation to Targovax’s fourth quarter 2022 presentation, Thursday 16 February
October 26, 2022 Press release - Regulatory Invitation to Targovax’s third quarter 2022 presentation, Thursday 3 November
August 18, 2022 Press release - Regulatory Targovax ASA: Second quarter and first half year 2022 results
May 11, 2022 Press release - Regulatory Targovax announces clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 melanoma trial
February 28, 2022 Press release - Regulatory Targovax ASA strengthens management with Lubor Gaal as Chief Financial Officer
February 9, 2022 Press release - Regulatory Targovax ASA: Invitation to presentation of Targovax’s fourth quarter 2021 results, Thursday 17 February
February 1, 2022 Press release - Regulatory Targovax and Prof. Michael Uhlin at Karolinska Institutet enter research collaboration
January 12, 2022 Press release - Regulatory Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation Norway
December 15, 2021 Press release - Regulatory Targovax awarded NOK 9.8m research grant by the Research Council of Norway towards the TG mutant RAS program
November 30, 2021 Press release - Regulatory Targovax ASA – Commencement of the subscription period for the rights issue
November 25, 2021 Press release - Regulatory Targovax ASA – Rights issue approved by the extraordinary general meeting
November 24, 2021 Press release - Regulatory Targovax ASA – Terms of the fully underwritten rights issue
November 4, 2021 Press release - Regulatory Targovax ASA – Key information relating to the preferential rights issue
August 18, 2021 Press release - Regulatory Targovax ASA: second quarter and first half year 2021 results
August 9, 2021 Press release - Regulatory Targovax ASA: Invitation to presentation of Targovax’s second quarter and first half 2021 results, Wednesday 18 August
July 1, 2021 Press release - Regulatory Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer
June 28, 2021 Press release - Regulatory Targovax to present at the 4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition
June 22, 2021 Press release - Regulatory Targovax receives Fast Track designation for ONCOS-102 in melanoma
June 17, 2021 Press release - Regulatory Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102 in combination with durvalumab in patients with advanced colorectal cancer with peritoneal malignancies
June 14, 2021 Press release - Regulatory Targovax releases presentations of ONCOS-102 mesothelioma 24-month data
March 4, 2021 Press release - Regulatory Targovax ASA: Registration of share capital increase following exercise of options
March 1, 2021 Press release - Regulatory Targovax ASA: Exercise of options under LTI program and resolution to increase the share capital
March 20, 2020 Press release - Non-regulatory Impact of corona virus (COVID-19) on Targovax’s operations
March 3, 2020 Press release - Non-regulatory Targovax announces completed enrollment in the ONCOS-102 trial in anti-PD1 refractory melanoma
March 3, 2020 Press release - Non-regulatory Targovax ASA: Invitation to presentation of Targovax’s fourth quarter 2019 results, Wednesday 11 March
November 11, 2019 Press release - Non-regulatory Presentation of ONCOS-102 melanoma data at SITC Annual Meeting
October 29, 2019 Press release - Non-regulatory Targovax ASA: Invitation to presentation of Targovax’s third quarter 2019 results, Thursday 7 November
October 9, 2019 Press release - Non-regulatory Targovax selected for oral presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting
September 24, 2019 Press release - Non-regulatory Targovax announces opening of Oslo University Hospital as site for ONCOS-102 trial in melanoma
July 31, 2019 Press release - Non-regulatory Targovax is invited to present at Solebury Trout European Biotech Investor Day in NYC
July 8, 2019 Press release - Regulatory Targovax announces encouraging results from part 1 of the ONCOS-102 and Keytruda combination trial in anti-PD1 refractory melanoma
June 3, 2019 Press release - Non-regulatory Targovax announces publication of in vivo abscopal effect of ONCOS-102 and Keytruda combination
May 23, 2019 Press release - Regulatory Targovax announces median and three-year overall survival for TG01 trial in resected pancreatic cancer
May 8, 2019 Press release - Non-regulatory Targovax announces completed enrollment of ONCOS-102 trial in mesothelioma
March 19, 2019 Press release - Non-regulatory Targovax is invited to present at Neoantigen Summit Europe, DNB SME Conference and BIO-Europe Spring
March 15, 2019 Press release - Regulatory Targovax signs clinical collaboration agreement with the Parker Institute for Cancer Immunotherapy and Cancer Research Institute
March 14, 2019 Press release - Non-regulatory Targovax grants Zelluna Immunotherapy an FTO license to intellectual property relating to mutant RAS T cell receptor technology
March 8, 2019 Press release - Non-regulatory Targovax announces Notice of Allowance in the US on patent covering the TG mutant-RAS neoantigen vaccine platform
February 11, 2019 Press release - Non-regulatory First patient treated in dose expansion cohort of Targovax’s ONCOS-102 trial in melanoma
February 4, 2019 Press release - Non-regulatory Targovax ASA: Announcement of fourth quarter and full year results 2018
January 17, 2019 Press release - Non-regulatory Targovax granted European Patent for mutant-RAS neoantigen platform lead products
November 28, 2018 Press release - Non-regulatory Targovax is invited to present at upcoming investor and industry conferences
October 26, 2018 Press release - Regulatory Targovax ASA: Announcement of third quarter 2018 financial results
October 15, 2018 Press release - Non-regulatory Targovax reports encouraging disease-free survival (DFS) data from TG01 trial in resected pancreatic cancer
October 12, 2018 Press release - Regulatory Agenda for Targovax Capital Markets Day 15 October 2018, in Oslo, Norway
October 11, 2018 Press release - Regulatory Targovax Key Opinion Leader Symposium on Oncolytic Viruses in New York City today, 11 October, 2018
October 4, 2018 Press release - Regulatory Targovax to host Capital Markets Day 15 October 2018, in Oslo, Norway
October 1, 2018 Press release - Regulatory Targovax presented ONCOS-102 poster at 13th International Adenovirus Meeting
September 27, 2018 Press release - Regulatory Targovax announces interim results from Phase I trial of ONCOS-102 in checkpoint inhibitor refractory melanoma
September 27, 2018 Press release - Regulatory Targovax to Host Key Opinion Leader Symposium on Oncolytic Viruses in New York City, 11 October 2018
September 13, 2018 Press release - Regulatory Targovax strengthens management team with the appointment of Torbjørn Furuseth as CFO; Erik Digman Wiklund to become CBO
August 23, 2018 Press release - Regulatory Targovax ASA: Second quarter and first half year 2018 results
July 12, 2018 Press release - Regulatory Targovax and SOTIO announce first patient dosed in Phase I/II combination trial of ONCOS-102 with DCVAC
June 19, 2018 Press release - Regulatory Targovax granted EU Patent for mutant-RAS neoantigen platform 2nd generation product TG02
June 11, 2018 Press release - Regulatory Targovax strengthens focus on ONCOS oncolytic virus development program
May 24, 2018 Press release - Regulatory Targovax strengthens 2-year survival rate in resected pancreatic cancer with TG01
May 2, 2018 Press release - Regulatory Targovax announces early signal of efficacy in ONCOS-102 trial in mesothelioma
April 12, 2018 Press release - Regulatory Targovax strengthens Board of Directors with the appointment of Catherine Wheeler
February 7, 2018 Press release - Regulatory Targovax announces completion of safety lead-in and preliminary immune activation data in ONCOS-102 trial in mesothelioma
January 8, 2018 Press release - Regulatory Targovax announces the appointment of Michael Bogenstaetter as Chief Business Officer
January 4, 2018 Press release - Regulatory Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients
December 18, 2017 Press release - Regulatory Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer
December 11, 2017 Press release - Regulatory Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews
October 12, 2017 Press release - Regulatory Targovax announces one-year survival rate and safety data in the modified cohort of the TG01 trial in resected pancreatic cancer
October 3, 2017 Press release - Regulatory Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02
September 25, 2017 Press release - Regulatory Targovax granted US Patent for mutant-RAS neoantigen platform lead products
June 6, 2017 Press release - Regulatory Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting
May 10, 2017 Press release - Regulatory Targovax recruits first patient into first ONCOS-102 /Checkpoint inhibitor melanoma study
April 20, 2017 Press release - Regulatory Targovax initiates first clinical trial with TG02, the second product from its RAS-peptide immunotherapy platform
April 6, 2017 Press release - Regulatory Targovax to present clinical data on its phase I/II clinical trial evaluating TG01 in resected pancreatic cancer at the ASCO Annual Meeting
March 22, 2017 Press release - Regulatory Targovax ASA: The board of directors of Oslo Stock Exchange approves transfer of Targovax ASA to the main list
March 17, 2017 Press release - Regulatory Targovax ASA applies for transfer to Oslo Stock Exchange main list
February 2, 2017 Press release - Regulatory Targovax announces encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients
January 5, 2017 Press release - Regulatory Targovax announces appointment of Erik Digman Wiklund as CFO
November 10, 2016 Press release - Regulatory Targovax granted European Patent for ONCOS platform lead product, ONCOS-102
November 2, 2016 Press release - Non-regulatory Targovax announces appointment of Oystein Soug as CEO
October 21, 2016 Press release - Non-regulatory Targovax presents ONCOS-102 scientific rationale at the European Society of Gene and Cell Therapy
August 25, 2016 Press release - Regulatory Targovax ASA: Interim Report second quarter and first half year 2016